Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zepzelca (Lurbinectedin),ZEP2021-US-001,2021,USA,MDV,350,68,45,55,26.5,62,78,12,15,30,40,15,45,30,15,10,20,35,45,18,8,5,10,7,25,35,40,Cisplatin + Etoposide,Carboplatin + Paclitaxel,Etoposide + Cisplatin,Irinotecan + Cisplatin,5,3,2,20,60,50,20,50,30,60,2
Zepzelca (Lurbinectedin),ZEP2022-EU-002,2022,Germany,Claim Database,420,72,48,52,27.1,58,75,15,12,28,42,18,42,32,16,10,18,33,49,20,10,6,12,8,22,38,38,Cisplatin + Etoposide,Carboplatin + Etoposide,Etoposide + Cisplatin,Paclitaxel + Carboplatin,6,4,3,22,62,52,18,52,30,62,3
Zepzelca (Lurbinectedin),ZEP2023-UK-003,2023,UK,MDV,280,70,46,54,26.8,60,77,14,14,29,41,16,44,31,15,10,19,34,47,19,9,5,11,7,24,36,39,Cisplatin + Etoposide,Carboplatin + Paclitaxel,Etoposide + Cisplatin,Irinotecan + Cisplatin,5,3,2,21,61,51,19,51,30,61,2.5
